SAB4200779
Anti-NRAS Antibody
rabbit polyclonal
Sinônimo(s):
GTPase NRas, Transforming protein N-Ras
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Código UNSPSC:
12352203
NACRES:
NA.41
Produtos recomendados
Nome do produto
Anti-NRAS (C-terminal) antibody produced in rabbit, IgG fraction of antiserum
fonte biológica
rabbit
Nível de qualidade
forma do anticorpo
IgG fraction of antiserum
tipo de produto de anticorpo
primary antibodies
clone
polyclonal
Formulário
buffered aqueous solution
peso molecular
predicted mol wt ~21 kDa
reatividade de espécies
human
validação aprimorada
recombinant expression
Learn more about Antibody Enhanced Validation
técnica(s)
immunoblotting: 1:2,000-1:4,000 using human HEK-293T cells over-expressing NRAS protein
nº de adesão UniProt
Condições de expedição
dry ice
temperatura de armazenamento
−20°C
modificação pós-traducional do alvo
unmodified
Informações sobre genes
human ... NRAS(4893)
Categorias relacionadas
Descrição geral
Transforming protein N-Ras (NRAS), also known as GTPase NRas or Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, is a member of the Ras protein family and are low molecular-weight GTPases. NRAS is mapped to human chromosome location 1p13.2 and shows ubiquitous expression. Ras proteins have highly homologous primary amino acid sequence and differ in their C-terminal region termed as hypervariable region (HVR).
Especificidade
Anti-NRAS (C-terminal) antibody specifically recognizes human NRAS and does not cross-react with HRAS or KRAS.
Imunogênio
Synthetic peptide from the internal region of human NRAS protein, conjugated to KLH
Aplicação
Anti-NRAS (C-terminal) antibody produced in rabbit has been used in immunoblotting.
Ações bioquímicas/fisiológicas
Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS) was the first melanoma oncogene to be identified. Oncogenic NRAS mutations are single base substitutions (most commonly affecting residues G12, G13, or Q61) that lead to the stabilization of GTP binding and constitutive activation of RAS and downstream signaling cascades. Abnormal NRAS activity stimulates several signaling pathways, including mitogen-activated protein kinase (MAPK/ERK), serine/threonine-protein kinase (RAFs) (ARAF, BRAF, and CRAF), phosphatidylinositol 3-kinase (PI3K) and the RAS-like protein (RAL) guanine nucleotide exchange factors (GEFs) signaling pathways. This leads to uncontrolled cell proliferation, resistance to apoptosis and thus cancer therapy potential target. NRAS mutations are present in various cancers, including melanomas, acute myeloid leukemia, colon, thyroid and lung cancers. Mutations are also implicated in hematologic malignancies, including acute lymphocytic leukemia, myelodysplastic syndrome, multiple myeloma and chronic myelomonocytic leukemia.
forma física
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Armazenamento e estabilidade
For continuous use, store at 2–8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.
Exoneração de responsabilidade
Unless otherwise stated in our catalog, our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Não está encontrando o produto certo?
Experimente o nosso Ferramenta de seleção de produtos.
Código de classe de armazenamento
10 - Combustible liquids
Classe de risco de água (WGK)
WGK 3
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Escolha uma das versões mais recentes:
Certificados de análise (COA)
Lot/Batch Number
Não está vendo a versão correta?
Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma
Puig-Butille JA, et al.
Experimental Dermatology, 22(2), 148-150 (2013)
Esther Castellano et al.
Genes & cancer, 2(3), 216-231 (2011-07-23)
H-ras, N-ras, and K-ras are canonical ras gene family members frequently activated by point mutation in human cancers and coding for 4 different, highly related protein isoforms (H-Ras, N-Ras, K-Ras4A, and K-Ras4B). Their expression is nearly ubiquitous and broadly conserved
Eva Muñoz-Couselo et al.
OncoTargets and therapy, 10, 3941-3947 (2017-09-02)
Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in 15%-20% of melanomas. The NRAS-mutant subset of melanoma is more
Ha Linh Vu et al.
Pharmacological research, 107, 111-116 (2016-03-19)
Cutaneous melanoma is a devastating form of skin cancer and its incidence is increasing faster than any other preventable cancer in the United States. The mutant NRAS subset of melanoma is more aggressive and associated with poorer outcomes compared to
Douglas B Johnson et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(16), 4186-4192 (2014-06-05)
Successful targeting of specific oncogenic "driver" mutations with small-molecule inhibitors has represented a major advance in cancer therapeutics over the past 10 to 15 years. The most common activating oncogene in human malignancy, RAS (rat sarcoma), has proved to be
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica